Zelda Therapeutics (ASX:ZLD) is focused on the medical cannabis sector.
See more information about Zelda Therapeutics
Zelda Therapeutics expands medical cannabis clinical trial
Zelda Therapeutics (ASX:ZLD) has expanded its medical cannabis clinical trial program in Chile to include autism, which is expected to commence in the second half of 2017.
Autism is a lifelong development disability characterized by impairments in social communication and interactions.
The global market for autism diagnosis and treatments is expected to grow to US$412.7 million by 2019.
Zelda will work together with Chilean non-profit patient advocate group Fundación Daya, leveraging their clinical experiences with autism patients.
Harry Karelis, executive chairman, commented: "Our investment into conducting a rigorous and controlled clinical trial paves the way for product registrations next year significantly improving patient access to a novel form of treatment.
"Our intention would be to replicate this trial in other key jurisdictions to rapidly improve patient access in other jurisdictions."